Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

A Huntington’s trial brings hope and grief

Erin Paterson
Conditions
November 4, 2025
Share
Tweet
Share

It’s been weeks since the news broke of UniQure’s trial successfully slowing the progression of HD, and I still find myself breaking down in tears. I have been going about my life, doing the groceries, going to the gym, cleaning the house, and the tears keep coming unexpectedly. I am happy about the news, but that is not how it feels in my body. I have come to realize I am experiencing grief.

There are so many mixed emotions in the community, and that is completely understandable.

This is the positive story the HD community has been waiting for. UniQure announced that its investigational gene therapy can slow progression of the disease. The therapy is being used in clinical trials to lower huntingtin while also exploring safety. As a clinical trial it not available to the community yet, but this is the first time a disease-modifying treatment has been on the horizon. This is a huge advancement for the HD community and we are all celebrating.

But

We are still in the trenches taking care of our sick loved ones. Whether you are parenting a child with JHD, caregiving for a parent, or supporting multiple people impacted by the disease, the reality of our daily lives has not changed. For many of those we love and care for, this breakthrough has not arrived in time.

There is fear that, if it’s’ approved, this treatment may not be accessible for everyone. We worry that it might not be available in our country, we might not qualify for treatment, we will not be able to afford it, or our symptoms will be too advanced. We also know there are a lot of hurdles to overcome before this treatment reaches the community. It needs to go through peer review and be approved by the FDA, and that’s just in the U.S. Then it has to be approved and rolled out around the world. It feels treacherous to get our hopes up too high.

This announcement brings to mind all of those who have already suffered and lost the battle with this disease. The potential treatment is too late for them, but that doesn’t stop us from wishing that things were different, that we could have them back, that they could have benefitted from this as well. Imagine how different our lives could have been.

Huntington’s disease is a part of our identity. Whether we are gene positive, gene negative, or untested, we have worked really hard to accept our fate in life. This announcement represents a fundamental shift in how we see ourselves. Although the shift is good, it’s uncomfortable. Now there is the possibility of a brighter future, and that can be unsettling because we don’t know what our future looks like anymore.

No matter how this news has impacted you, no matter what emotions you are experiencing, even if you can’t quite identify what you are feeling, it’s OK to feel the way that you do. Your emotions are not wrong.

Living with Huntington’s disease in the family is very complex, and so is thinking about this potential treatment. Not only do we need to consider the impacts for ourselves personally, we also have to think of everyone in our family.

And soon, if we are lucky, and this treatment is approved in the countries where we live, we will face another set of important questions. Do I want to go through this treatment? Is this the right treatment for me? It’s a very personal decision, and everyone has the right to make their own choices around accessing treatment, or not, just as they do with deciding to go through genetic testing or having children who are at risk. This potential treatment involves a lengthy brain surgery. Perhaps now that huntingtin-lowering could be a viable strategy, it will push along other treatments in development, and maybe those won’t be as invasive.

There are so many unknowns.

For now I am focusing on the renewed hope this announcement has given me and trying to shift my thinking from being someone who is 100 percent guaranteed to get HD, because I am gene positive, to someone who just might not. I have to come to terms with this new reality.

I am beyond grateful to everyone who has worked so tirelessly to get us to this point, including all the scientists searching for a treatment, the drug companies investing in finding effective treatments, and the brave individuals who participated not only in this clinical trial but in all the ones that have come before. I am grateful as well for the patient advocacy organizations that have been supporting us along the way, not just with understanding clinical trials but also with the complexity of our everyday lives. We are all part of a wonderful community, and we will be there to support each other no matter what.

Erin Paterson is a writer and the author of Huntington’s Disease Heroes: Inspiring Stories of Resilience from the HD Community and All Good Things: A Memoir About Genetic Testing, Infertility and One Woman’s Relentless Search for Happiness.

ADVERTISEMENT

Prev

How misinformation endangers our progress against preventable diseases [PODCAST]

November 3, 2025 Kevin 0
…
Next

What is professional inertia in medicine?

November 4, 2025 Kevin 0
…

Tagged as: Neurology

Post navigation

< Previous Post
How misinformation endangers our progress against preventable diseases [PODCAST]
Next Post >
What is professional inertia in medicine?

ADVERTISEMENT

More by Erin Paterson

  • Why the words doctors use matter more than they think

    Erin Paterson
  • Embracing the Huntington’s disease community

    Erin Paterson
  • The heartbreaking realities of being a caregiver with Huntington’s disease

    Erin Paterson

Related Posts

  • In the face of uncertainty, choose hope over fear

    Shreya Kumar
  • Tackling trial delays, social inflation, and skeptical jurors in a pandemic world

    Marco Spadacenta, JD
  • A touching tale of hope and uncertainty in the hospital

    Elizabeth Rodriguez
  • Beyond opioids: a new hope for chronic pain relief

    L. Joseph Parker, MD
  • Unsolicited advice from unmatched residency applicants: Hope for the best, plan for the worst

    Katherine Yu, MD and Shaan Somani
  • The emotional side of genetic testing

    Erin Paterson

More in Conditions

  • Why dietary advice changes: It is not the food, it is the world

    Gerald Kuo
  • Blood in urine after a child’s injury: When to worry

    Martina Ambardjieva, MD, PhD
  • Living with vitiligo: Overcoming shame and control

    Dr. Reshma Stanislaus
  • Post-stroke cognitive impairment: the hidden challenge of recovery

    Rida Ghani
  • The milkweed and the wind: a poem on aging as renewal

    Michele Luckenbaugh
  • Alex Pretti’s death: Why politics belongs in emergency medicine

    Marilyn McCullum, RN
  • Most Popular

  • Past Week

    • The hidden costs of the physician non-clinical career transition

      Carlos N. Hernandez-Torres, MD | Physician
    • The gastroenterologist shortage: Why supply is falling behind demand

      Brian Hudes, MD | Physician
    • AI-enabled clinical data abstraction: a nurse’s perspective

      Pamela Ashenfelter, RN | Tech
    • Why private equity is betting on employer DPC over retail

      Dana Y. Lujan, MBA | Policy
    • Leading with love: a physician’s guide to clarity and compassion

      Jessie Mahoney, MD | Physician
    • Why voicemail in outpatient care is failing patients and staff

      Dan Ouellet | Tech
  • Past 6 Months

    • Physician on-call compensation: the unpaid labor driving burnout

      Corinne Sundar Rao, MD | Physician
    • How environmental justice and health disparities connect to climate change

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Policy
    • Will AI replace primary care physicians?

      P. Dileep Kumar, MD, MBA | Tech
    • A physician father on the Dobbs decision and reproductive rights

      Travis Walker, MD, MPH | Physician
    • What is the minority tax in medicine?

      Tharini Nagarkar and Maranda C. Ward, EdD, MPH | Education
    • Why the U.S. health care system is failing patients and physicians

      John C. Hagan III, MD | Policy
  • Recent Posts

    • Why dietary advice changes: It is not the food, it is the world

      Gerald Kuo | Conditions
    • Blood in urine after a child’s injury: When to worry

      Martina Ambardjieva, MD, PhD | Conditions
    • Managing a Black Swan in health care: a lesson in transparency

      Joseph Pepe, MD | Physician
    • Health care as a human right vs. commodity: Resolving the paradox

      Timothy Lesaca, MD | Physician
    • Why voicemail in outpatient care is failing patients and staff

      Dan Ouellet | Tech
    • Living with vitiligo: Overcoming shame and control

      Dr. Reshma Stanislaus | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The hidden costs of the physician non-clinical career transition

      Carlos N. Hernandez-Torres, MD | Physician
    • The gastroenterologist shortage: Why supply is falling behind demand

      Brian Hudes, MD | Physician
    • AI-enabled clinical data abstraction: a nurse’s perspective

      Pamela Ashenfelter, RN | Tech
    • Why private equity is betting on employer DPC over retail

      Dana Y. Lujan, MBA | Policy
    • Leading with love: a physician’s guide to clarity and compassion

      Jessie Mahoney, MD | Physician
    • Why voicemail in outpatient care is failing patients and staff

      Dan Ouellet | Tech
  • Past 6 Months

    • Physician on-call compensation: the unpaid labor driving burnout

      Corinne Sundar Rao, MD | Physician
    • How environmental justice and health disparities connect to climate change

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Policy
    • Will AI replace primary care physicians?

      P. Dileep Kumar, MD, MBA | Tech
    • A physician father on the Dobbs decision and reproductive rights

      Travis Walker, MD, MPH | Physician
    • What is the minority tax in medicine?

      Tharini Nagarkar and Maranda C. Ward, EdD, MPH | Education
    • Why the U.S. health care system is failing patients and physicians

      John C. Hagan III, MD | Policy
  • Recent Posts

    • Why dietary advice changes: It is not the food, it is the world

      Gerald Kuo | Conditions
    • Blood in urine after a child’s injury: When to worry

      Martina Ambardjieva, MD, PhD | Conditions
    • Managing a Black Swan in health care: a lesson in transparency

      Joseph Pepe, MD | Physician
    • Health care as a human right vs. commodity: Resolving the paradox

      Timothy Lesaca, MD | Physician
    • Why voicemail in outpatient care is failing patients and staff

      Dan Ouellet | Tech
    • Living with vitiligo: Overcoming shame and control

      Dr. Reshma Stanislaus | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...